牛国晨,闫子光,张碧辉,杨敏,邹英华

• 1:北京大学第一医院介入血管外科

摘要(Abstract)：

<正>肾血管性高血压是由肾动脉狭窄造成的继发性高血压。肾动脉狭窄是继发性高血压最常见的原因之一。在重症高血压患者[即收缩压高于180mm Hg(1mm Hg=0.133k Pa)和（或）舒张压高于100mm Hg]、年轻高血压患者以及同时患有糖尿病的高血压患者中，肾动脉狭窄的患病率可达20%～80%~([1])。1978年Grüntzig等~([2])报道了第1例球囊扩张治疗肾动脉狭窄。由于腔内成形术治疗具有微创、可重复等优势，从20世纪90年代开始，腔内成形术逐渐代替外科手术成为治疗肾动脉狭窄的首选方法。

关键词(KeyWords)： 肾动脉狭窄;高血压;腔内成形术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 牛国晨,闫子光,张碧辉,杨敏,邹英华

参考文献(References)：

• [1]蒋雄京，邹玉宝.肾动脉狭窄的诊断和处理中国专家共识[J].中国循环杂志，2017,32(9):835-844.
• [2] Grüntzig A,Kuhlmann U,Vetter W,et al. Treatment o f renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis[J]. Lancet,1978,1(8068):801-802.
• [3] Xiong HL,Peng M,Jiang XJ,et al. Time trends regarding the etiology of renal artery stenosis:18 years’ experience from the China Center for Cardiovascular Disease[J]. J Clin Hypertens(Greenwich),2018,20(9):1302-1309.
• [4] Cooper CJ,Murphy TP,Cutlip DE,et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis[J]. N Engl J Med,2014,370(1):13-22.
• [5]王倩，蒋雄京，何际宁，等.肾动脉狭窄致心力衰竭患者的临床特征及诊治经验[J].实用心脑肺血管病杂志，2021,29(6):116-123.
• [6] Ritchie J,Green D,Chrysochou C,et al. High-risk clinical presentations in atherosclerotic renovascular disease:prognosis and response to renal artery revascularization[J]. Am J Kidney Dis,2014,63(2):186-197.
• [7] Davies MG,Saad WE,Bismuth JX,et al. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney[J]. J Vasc Surg,2009,49(4):953-960.
• [8] Cadour F,Silhol F,Iline N,et al. Insights from intravascular pressure measurement of renal artery revascularization in patients with fi bromuscular dysplasia:the DYSART study[J]. J Vasc Surg,2022,75(3):939-949.
• [9] Li K,Cui M,Zhang K,et al. Clinical characteristics a n d long-term outcomes of endovascular treatment of renal artery fi bromuscular dysplasia with branch lesions[J]. Pediatr Nephrol,2021,36(10):3169-3180.
• [10] Tian Y,Yuan B,Zhang N,et al. Outcomes following the endovascular treatment of renal artery stenosis caused by fi bromuscular dysplasia:a systematic review and meta-analysis[J].Ann Vasc Surg,2022,78:362-372.
• [11] Kinjo H,Kafa A. The results of treatment in renal artery stenosis due to Takayasu disease:comparison between surgery,angioplasty,and stenting. A monocentrique retrospective study[J].G Chir,2015,36(4):161-167.
• [12] Peng M,Ji W,Jiang X,et al. Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis:two-year results[J]. Int J Cardiol,2016,205:117-123.
• [13] Iwasaki T,Mishima E,Suzuki T,et al. Kidney enlargement ef fect of angioplasty for nonatherosclerotic renovascular disease:reversibility of ischemic kidney[J]. Hypertens Res,2020,43(11):1214-1221.
• [14] Sgueglia GA,Todaro D,Pucci E. Vascular imaging balloon with local drug delivery for the treatment of renal artery recurrent in-stent restenosis[J]. Cardiovasc Revasc Med,2014,15(3):186-189.
• [15] Di Palma G,Cortese B. Intravascular lithotripsy and dual drugcoated balloons for the treatment of severely calcifi c renal in-stent restenosis:all is fair in war[J]. Cardiovasc Revasc Med,2021,28S:193-196.
• [16] Zeller T,Rastan A,Schwarzw?lder U,et al. Treatment of instent restenosis following stent-supported renal artery angioplasty[J]. Catheter Cardiovasc Interv,2007,70(3):454-459.
• [17] Bradaric C,Eser K,Preuss S,et al. Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease[J]. EuroIntervention,2017,13(2):e248-e255.
• [18] Lederman RJ,Mendelsohn FO,Santos R,et al. Primary renal artery stenting:characteristics and outcomes after 363procedures[J]. Am Heart J,2001,142(2):314-323.
• [19] Ros?awiecka A,Kab?ak-Ziembicka A,Badacz R,et al. Longterm outcomes and determinants of stenosis recurrence after renal artery angioplasty in hypertensive patients with renovascular disease[J]. Postepy Kardiol Interwencyjnej,2020,16(1):65-75.
• [20]郑斌，颜红兵，程姝娟，等.西罗莫司洗脱支架治疗小直径肾动脉狭窄的长期随访[J].中国介入心脏病学杂志，2010,18(5):262-265.
• [21] Jundt MC,Takahashi EA,Harmsen WS,et al. Restenosis rates after drug-eluting stent treatment for stenotic small-diameter renal arteries[J]. Cardiovasc Intervent Radiol,2019,42(9):1293-1301.
• [22] Bax L,Woittiez AJ,Kouwenberg HJ,et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function:a randomized trial[J]. Ann Intern Med,2009,150(12):840-848,W150-W151.
• [23] ASTRAL Inv estigators,Wheatley K,Ives N,et al. Revascularization versus medical therapy for renal-artery stenosis[J]. N Engl J Med,2009,361(20):1953-1962.
• [24] Zeller T,Krankenberg H,Erglis A,et al. A randomized,multi-center,prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis(RADAR)-one-year results of a pre-maturely terminated study[J]. Trials,2017,18(1):380.
• [25] Lin Z,Zhang B,Lin L,et al. Blood oxygen level dependent magnetic resonance imaging to predict split renal function improvement after renal artery stenting[J]. Eur J Vasc Endovasc Surg,2022,63(4):659-660.